Salvatore Turano, Candida Mastroianni, Caterina Manfredi, Rosalbino Biamonte, Silvia Ceniti, Virginia Liguori, Rosanna De Simone, Serafino Conforti, Aldo Filice, Antonio Rovito, Caterina Viscomi, Giuseppe Patitucci, Salvatore Palazzo
The esthesioneuroblastoma is a rare neuroendocrine tumor that derives from the olfactory cells. In the last 20 years, around 1,000 cases have been described, with an overall survival rate of 60-70% at 5 years. The most common symptoms are nasal bleeding, nasal clogging and, in locally advanced cases, signs/symptoms of intracranic hypertension such as papilla edema, cefalea, and vomiting. The standard treatments are surgery and radiotherapy. Chemotherapy can be used in an adjuvant/neoadjuvant setting and in the metastatic phase, even if its role is still not established with certainty...
May 2010: Journal of Neuro-oncology